🔎 Trials Near Me

Akèy › Obèsite › New York

Etid klinik pou Obèsite nan New York

75 etid pou Obèsite ap chèche patisipan nan sit nan New York.

Vil nan New York

Tèks ofisyèl etid la (Anglè)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • Rochester Clinical Research /ID# 282484, Rochester
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07752979

Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy

  • State University of New York at Buffalo, South Campus, Buffalo
Ap rekrite
Laj 18 a 60 · Tout sèks · Mizajou Oct 2, 2026 · NCT07641361

Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients

  • Weill Cornell -1300 York Avenue, New York
  • Lenox Hill Hospital | Northwell Health, New York
Ap rekrite
Laj 21 a 65 · Tout sèks · Mizajou Oct 1, 2026 · NCT07090005

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

  • Rochester Clinical Research - Buffalo, Buffalo
  • CHEAR Center LLC, The Bronx
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07783802

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

  • Southgate Medical Group, LLP, West Seneca
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07533175

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  • UBMD Physicians Group - Pediatrics - Conventus, Buffalo
  • SUNY Upstate Medical Univ - Syracuse, Syracuse
  • Advantage Clinical Trials, The Bronx
Ap rekriteFaz 3
Laj 8 a 18 · Tout sèks · Mizajou Sep 30, 2026 · NCT07253285

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

  • Rochester Clinical Research, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07685808

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

  • ALSA Research-Manhattan, New York
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT07837973

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  • Comprehensive Weight Ctrl Prog, New York
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07720271

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

  • Ichor Research, Syracuse
  • Southgate Medical Group, LLP, West Seneca
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07668414

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

  • Weill Cornell Medicine - Comprehensive Weight Control Center, New York
  • Rochester Clinical Research, LLC, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07595549

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • New York Gastroenterology Associates, New York
  • Care Access - Yonkers, Yonkers
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • UBMD Pediatrics, Buffalo
Ap rekriteFaz 3
Laj 6 a 17 · Tout sèks · Mizajou Sep 24, 2026 · NCT06672549

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Icahn School of Medicine at Mount Sinai, New York
  • New York Gastroenterology Associates, New York
  • Care Access - Yonkers, Yonkers
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937086

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

  • New York Gastroenterology Associates, New York
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07339423

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  • NYC Research INC, Long Island City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  • NYU Langone Health, New York
  • Weill Cornell Medical College, New York
  • IMA Clinical Research Manhattan, New York
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07392190

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  • Rochester Clinical Research - Buffalo, Buffalo
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07369011

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Velocity Clinical Research - Binghamton, Binghamton
  • Hudson Valley Cardiovascular Practice PC, Poughkeepsie
  • Rochester Clinical Research, Rochester
  • ak 2 plis
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • Rochester Clinical Research, LLC, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07321886

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  • Ellipsis Research Group - Brooklyn - 7th Street, Brooklyn
  • Rochester Clinical Research - Buffalo, Buffalo
  • NYC Research INC, Long Island City
  • ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07353931

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • Dent Neurologic Institute, Amherst
  • Rochester Clinical Research, LLC, Rochester
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 22, 2026 · NCT07589608

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, New Windsor
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, East Northport
  • AURORA-2 Clinical Site, East Syracuse
  • AURORA-2 Clinical Site, New Windsor
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743450

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  • Capital Cardiology Associates, Albany
  • Icahn School of Medicine at Mount Sinai, New York
  • Hudson Valley Cardiovascular Practice PC, Poughkeepsie
  • ak 1 plis
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Sep 16, 2026 · NCT07037459

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

  • NYC Research INC, Long Island City
  • Richmond University Medical Center, Staten Island
  • Southgate Medical Group, West Seneca
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT06897475

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  • Rochester Clinical Research, Buffalo
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351045

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Albany
  • ACCOMPLISH-2 Research Site, Albany
  • ACCOMPLISH-2 Research Site, Brooklyn
  • ak 1 plis
Ap rekriteFaz 3Volontè an sante akeyi
Laj 18 a 79 · Tout sèks · Mizajou Sep 11, 2026 · NCT07654374

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • Dent Neurologic Institute, Amherst
  • Velocity Clinical Research, Syracuse, East Syracuse
  • Rochester Clinical Research, LLC, Rochester
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT06143956

Graded Insulin Suppression Test P&F

  • Columbia University Irving Medical Center, New York
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Sep 8, 2026 · NCT06592261

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Albany
  • Kailera Clinical Site, Laurelton
  • Kailera Clinical Site, New York
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Velocity Clinical Research- Binghamton, Binghamton
  • Rochester Clinical Research, Rochester
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684235

Alpelisib Challenge Test (ACT)

  • Columbia University Irving Medical Center, New York
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Sep 3, 2026 · NCT07778524

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  • Kailera Clinical Site, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284875

Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

  • Mexican Consulate's Ventanilla de Salud (VDS), New York
Ap rekriteFaz 2Volontè an sante akeyi
Laj 21 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT05770570

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

  • Kailera Clinical Site, Albany
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT07284979

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  • Icahn School of Medicine at Mount Sinai, New York
  • Rochester Clinical Research, Rochester
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Aug 27, 2026 · NCT07575399

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.